Case Report: Transitioning to a Mixed-Oil Intravenous Lipid Emulsion in an Adult Patient Receiving Home Parenteral Nutrition.
Fat Emulsions, Intravenous
/ administration & dosage
Fatty Acids, Omega-6
/ adverse effects
Female
Fish Oils
/ administration & dosage
Health Status
Humans
Intestinal Diseases
/ complications
Liver
/ drug effects
Liver Diseases
/ complications
Liver Function Tests
Olive Oil
/ administration & dosage
Parenteral Nutrition, Home
/ adverse effects
Risk Factors
Soybean Oil
/ administration & dosage
Treatment Outcome
Triglycerides
/ administration & dosage
Young Adult
adverse effects
intestinal failure
intravenous fat emulsions
liver diseases
parenteral nutrition
Journal
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
ISSN: 1941-2452
Titre abrégé: Nutr Clin Pract
Pays: United States
ID NLM: 8606733
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
pubmed:
4
9
2019
medline:
16
6
2021
entrez:
4
9
2019
Statut:
ppublish
Résumé
A potential risk of long-term parenteral nutrition (PN) is intestinal failure-associated liver disease (IFALD). One recommendation for mitigating risk is limiting the fat dose to reduce the harmful effects of the ω-6 fatty acids, which are the main ingredient in traditional fats. SMOFlipid (SMOF) (Kabi-Fresenius, Bad Homburg, Germany) is a combination of soybean oil, medium-chain triglycerides, olive oil, and fish oil emulsion. This fat source may alleviate the risk of IFALD and improve liver function tests. A patient with a long history of PN reliance and IFALD is presented in this case report. After 4 months on SMOF, total and direct bilirubin levels improved.
Substances chimiques
Fat Emulsions, Intravenous
0
Fatty Acids, Omega-6
0
Fish Oils
0
Olive Oil
0
Triglycerides
0
Soybean Oil
8001-22-7
SMOFlipid
C9H2L21V7U
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
871-884Informations de copyright
© 2019 American Society for Parenteral and Enteral Nutrition.
Références
O'Keefe SJD, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. Short bowel syndrome and intestinal failure: Consensus definitions and overview. Clin Gastroenterol Hepatol. 2006;4 (1):6-10.
Pironi L, Arends J, Baxter J, et al. ESPEN endorsed recommendations: definition and classification of intestinal failure in adults. Clin Nutr. 2015;34(2):171-180.
Harrison E, Allan P, Ramu A, Vaidya A, Travis S, Lal S. Management of intestinal failure in inflammatory bowel disease: small intestinal transplantation or home parenteral nutrition? World J Gastroenterol. 2014;20(12):3153-3163.
Mundi MS, Salonen BR, Bonnes S. Home parenteral nutrition: Fat emulsions and potential complications. Nutr Clin Pract. 2016;31(5):629-641.
Staun M, Pironi L, Bozzetti, F et al. ESPEN guidelines on parenteral nutrition: home parenteral nutrition (HPN) in adult patients. Clin Nutr. 2009;28(4):467-479.
Dai YJ, Sun LL, Li MY, et al. Comparison of formulas based on lipid emulsions of olive oil, soybean oil, or several oils for parenteral nutrition: a systematic review and meta-analysis. Adv Nutr. 2016;7(2):279-286.
Lal S, Pironi L, Wanten G, et al. Clinical approach to the management of intestinal failure associated liver disease (IFALD) in adults: a position paper from the Home Artificial Nutrition and Chronic Intestinal Failure special interest group of ESPEN. Clin Nutr. 2018;37(6a):1794-1797.
U.S. Department of Health and Human Services, U.S. Food & Drug Administration, Drug Approvals and Databases; SMOFlipid (Lipid Injectable Emulsion), Company: Fresenius Kabi USA, LLC, Application No.: 207648, Approval Date: 07/13/2016. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207648Orig1s000TOC.cfm. Published January 12, 2018. Accessed January 21, 2019.
Bond A, Hayes S, Abraham A, et al. Reversal of intestinal failure associated liver disease fibrosis in a patient receiving long term home parenteral nutrition. Clin Nutr ESPEN. 2018;28:228-231.
Hurt RT, Mundi MS. Use of mixed-oil fat emulsion to improve intestinal failure-associated liver disease in long-term home parenteral nutrition: a case report. JPEN J Parenter Enteral Nutr. 2017;41(suppl_1):17s-19s.
Kinikini M. Effect of measuring gamma-glutamyl transpeptidase and using Smoflipid in a parenteral nutrition infusion in a patient with severe malabsorption and overlapping primary sclerosing cholangitis and ulcerative colitis. JPEN J Parenter Enteral Nutr. 2017; 41(suppl_1):24s-27s.
Klek S, Chambrier C, Singer P. Four-week parenteral nutrition using a third generation lipid emulsion (SMOFlipid)-A double blind, randomised, multicentre study in adults. Clin Nutr. 2013;32(2):224-231.
Lam K, Schiano T, Fiel MI, Iyer K. Index use of Smoflipid in a tertiary intestinal rehabilitation and transplantation program. JPEN J Parenter Enteral Nutr. 2017;41(suppl_1):20s-23s.
Mundi MS, McMahon MT, Carnell JJ, Hurt RT. Long-term use of mixed-oil lipid emulsion in adult home parenteral nutrition patients: a case series. Nutr Clin Pract. 2018;33(6)851-857.
Mundi MS, Kuchkuntla AR, Salonen BR, Bonnes S, Hurt RT. Long-term use of mixed-oil emulsion in soybean oil-intolerant home parenteral nutrition patients. JPEN J Parenter Enteral Nutr. 2019; https://doi.org/10.1002/jpen.1526
Osowska S, Kunecki M, Sobocki J, et al. Effect of changing the lipid component of home parenteral nutrition in adults. Clin Nutr. 2018;38(3):1355-1361.
Pironi L, Guidetti M, Verrastro O, et al. Functional lipidomics in patients on home parenteral nutrition: Effect of lipid emulsions. World J Gastroenterol. 2017;23(25): 4604-4614.
Martinelli M, Staiano A. Hirschsprung's disease and intestinal neuronal dysplasia. In: Textbook of Pediatric Gastroenterology, Hepatgology and Nutrition. 1st ed. Switzerland: Springer International Publishing; 2016.
Toldedo de Arruda Lourencao PL, Terra SA, Ortolan EV, Rodrigues MA. Intestinal neuronal dysplasia type B: a still little known diagnosis for organic causes of intestinal chronic constipation. World J Gastrointest Pharmacol Ther. 2016;7(3):397-405.
Meier-Ruge WA, Bruder E, Kapur RP. Intestinal neuronal dysplasia Type B: One giant gangliocyte is not good enough. Ped Devel Path. 2006;9(6):444-452.
Puri P, Intestinal neuronal dysplasia. Sem Ped Surg. 2003;12(4):259-264.
Katz S, Weinderman S. Osteoporosis and gastrointestinal disease. Gastroenterol Hepatol. 2010;6(8):506-517.
Academy of Nutrition and Dietetics Evidence Analysis Library, Quality Criteria Checklist - Primary Research. https://www.andeal.org/evidence-analysis-manual Copyright 2019.
Calder PC, Yaqoob P, Harvey DJ, Watts A, Newsholme EA. Incorporation of fatty acids by concanavalin A-stimulated lymphocytes and the effect on fatty acid composition and membrane fluidity. Biochem J. 1994;300(pt 2):509-518.
Pastor-Clerigues A, Marti-Bonmati E, Milara J, Almudever P, Cortijo J. Anti-inflammatory and anti-fibrotic profile of fish oil emulsions used in parenteral nutrition-associated liver disease. PLoS ONE. 2014;9(12):e115404.
Van Gossum A, Pironi L, Messing B, et al. Transient elastography (FIbroScan) is not correlated with liver fibrosis but with cholestasis in patients with long term home parenteral nutrition. J Parenter Enter Nutr. 2015;39(6):719-724.